Agents and Actions

, Volume 16, Issue 6, pp 527–534 | Cite as

Effects of benoxaprofen on the binding to and inactivation of leucoattractants by human polymorphonuclear leucocytesin vitro

  • R. Anderson
  • P. T. Lukey
  • C. E. J. van Rensburg
Immunosuppression and Inflammation


Benoxaprofen was previously found to inhibit the random and leucoattractant-induced migration of human polymorphonuclear leucocytesin vitro by a pro-oxidative mechanism [1]. In this study the effects of benoxaprofen on the binding to PMNL of the synthetic chemotactic tripeptide FMLP, on the oxidative inactivation of this leucoattractant by PMNL and on PMNL chemotaxis, chemokinesis and orientation in an FMLP gradient have been investigated. At concentrations of 10−5M (3 μg/ml) benoxaprofen inhibited PMNL random and leucoattractant-induced migration and increased PMNL membraneassociated oxidative metabolism and cellular auto-oxidation. These effects of benoxaprofen on PMNL migration and auto-oxidation were prevented by the anti-oxidant cysteine (10−3M). Benoxaprofen inhibited both FMLP-induced chemotaxis and chemokinesis but did not affect the binding of radiolabelled FMLP to PMNL or orientation of the cells in a positive gradient of the leucoattractant. Benoxaprofen at concentrations of 5×10−5M significantly increased the oxidative inactivation of FMLP by PMNL. Inhibition of PMNL migration by benoxaprofen is mediated by the two different pro-oxidative mechanisms, viz. a cell-directed auto-oxidative mechanism and potentiation of the oxidative inactivation of leucoattractants by PMNL.


Cysteine Oxidative Metabolism Positive Gradient Benoxaprofen Oxidative Inactivation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    R. Anderson, P.T. Lukey, S.P.E. Naudé andG. Jooné,Benoxaprofen: a pro-oxidant anti-inflammatory drug? Agents and Actions14, 238–246 (1984).CrossRefPubMedGoogle Scholar
  2. [2]
    C.H. Cashen, W. Dawson andE.A. Kitchen,The pharmacology of benoxaprofen 2-(4-chorophenyl)-α-methyl-5-benoxazole acetic acid, LCRL 3794 a new compound with anti-inflammatory activity apparently unrelated to inhibition of prostaglandin synthesis, J. Pharm. Pharmac.29, 330–336 (1977).Google Scholar
  3. [3]
    S.C.R. Meacock, G.W. Civil, W. Dawson andE.A. Kitchen,Studies on leucocyte-drug interaction with benoxaprofen, Eur. J. Rheumatol. Inflammation5, 51–60 (1982).Google Scholar
  4. [4]
    J.R. Walker andW. Dawson,Inhibition of rabbit PMN lipoxygenase activity by benoxaprofen, J. Pharm. Pharmac.31, 778–780 (1979).Google Scholar
  5. [5]
    J.R. Walker, J.C. Boot, B. Cox andW. Dawson,Inhibition of the release of slow-reacting substance of anaphylaxis by inhibitors of lipoxygenase activity, J. Pharm. Pharmac.32 866–867 (1980).Google Scholar
  6. [6]
    S.C.R. Meacock andE.A. Kitchen,Effects of the non-steroidal anti-inflammatory drug benoxaprofen on leucocyte migration, J. Pharm. Pharmac.31, 336–370 (1979).Google Scholar
  7. [7]
    E.J. Goetzl andF.H. Valone,Selective immobilization of human mononuclear phagocytes by benoxaprofen, Arthritis Rheum.25, 1486–1489 (1982).PubMedGoogle Scholar
  8. [8]
    R.A. Clark andS.J. Klebanoff,Chemotactic factor inactivation by the myeloperoxidase-hydrogen peroxide-halide system: an inflammatory control mechanism, J. clin. Invest.64, 913–920 (1979).PubMedGoogle Scholar
  9. [9]
    R.A. Clark,Chemotactic factors trigger their own oxidative inactivation by human neutrophils, J. Immun.129, 2725–2728 (1982).PubMedGoogle Scholar
  10. [10]
    A. Kamal andI.M. Koch,Pharmacokinetic studies of benoxaprofen in geriatric patients, Eur. J. Rheumatol. Inflammation5, 76–81 (1982).Google Scholar
  11. [11]
    S.H. Zigmond andJ.G. Hirsch,Leukocyte locomotion and chemotaxis — new methods for evaluation and demonstration of a cell-derived chemotactic factor, J. exp. Med.137, 387–410 (1973).CrossRefPubMedGoogle Scholar
  12. [12]
    S.H. Zigmond,Ability of polymorphonuclear leucocytes to orient in gradients of chemotactic factors, J. Cell Biol.75, 606–616 (1977).CrossRefPubMedGoogle Scholar
  13. [13]
    R.C. Prokesch andW.L. Hand,Antibiotic entry into human polymorphonuclear leukocytes, Antimicrob. Ag. Chemother.21, 373–380 (1982).Google Scholar
  14. [14]
    R. Anderson andP.T. Jones,Increased leucoattractant binding and reversible inhibition of neutrophil motility mediated by the peroxidase/H 2 O 2/halide system: effects of ascorbate, cysteine, dithiothreitol, levamisole and thiamine, Clin. exp. Immunol.47, 487–496 (1982).PubMedGoogle Scholar
  15. [15]
    A.S. Ridolfo, R. Nickander andW.M. Mikulaschek,Fenoprofen and benoxaprofen, Clinics in Rheumatic Diseases5, 393–410 (1979).Google Scholar
  16. [16]
    J. Ferguson, H.A. Addo, P.E. McGill, K.R. Woodcock, B.E. Johnson andW. Frain-Bell,A study of benoxaprofen-induced photosensitivity, Br. J. Derm.107, 429–442 (1982).Google Scholar
  17. [17]
    G.H. Findlay andP.R. Hull,Eruptive tumours on sun-exposed skin after benoxaprofen, Lanceti, 95 (1982).CrossRefGoogle Scholar
  18. [18]
    S.A. Weitzman andT.P. Stossel,Effects of oxygen radical scavengers and anti-oxidants on phagocyteinduced mutagenesis, J. Immun.128, 2770–2772 (1982).PubMedGoogle Scholar
  19. [19]
    W.R. Henderson andM. Kaliner,Mast cell granule peroxidase: location, secretion and SRS-A inactivation, J. Immun.122, 1322–1328 (1979).PubMedGoogle Scholar
  20. [20]
    W.R. Henderson, A. Jorg andS.J. Klebanoff,Eosinophil peroxidase-mediated inactivation of leukotrienes B 4,C 4 and D 4, J. Immun.128, 2609–2613 (1982).PubMedGoogle Scholar
  21. [21]
    M. Shadworth,Side effects of benoxaprofen, Br. med. J.285, 136 (1982).Google Scholar
  22. [22]
    I.F. Anderson, S.P.E. Naudé, H.A. Eftychis, R. Anderson andE. de Klerk,Anti-rheumatic effect of benoxaprofen, S. Afr. med. J.63, 923–925 (1983).PubMedGoogle Scholar
  23. [23]
    B.R. Allen,Benoxaprofen and the skin, Br. J. Derm.109, 361–364 (1983).Google Scholar

Copyright information

© Birkhäuser Verlag 1985

Authors and Affiliations

  • R. Anderson
    • 1
  • P. T. Lukey
    • 1
  • C. E. J. van Rensburg
    • 1
  1. 1.Division of Immunology, Department of Medical Microbiology, Institute for PathologyUniversity of PretoriaPretoriaRepublic of South Africa

Personalised recommendations